Shine Therapeutics will initially focus on developing and commercializing lutetium-177 (Lu-177), but it is also evaluating additional medical isotopes with therapeutic properties, according to the company. Shine signed an agreement in May with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to license a method for producing Lu-177.
Katrina Pitas has been named as vice president and general manager of the new division. A 10-year company veteran, Pitas previously served as Shine's vice president of business development.
Copyright © 2019 AuntMinnie.com